Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 184

The DOI matches its Crossref record.

Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin–Tazobactam Compared to Those on Vancomycin and Cefepime

Open access
Navalkele, Bhagyashri, Pogue, Jason M., Karino, Shigehiko, Nishan, Bakht, Salim, Madiha, Solanki, Shantanu, Pervaiz, Amina, Tashtoush, Nader, Shaikh, Hamadullah, Koppula, Sunitha, Koons, Jonathan, Hussain, Tanveer, Perry, William, Evans, Richard, Martin, Emily T., Mynatt, Ryan P., Murray, Kyle P., Rybak, Michael J., Kaye, Keith S.·2017·Clinical Infectious Diseases

Abstract

BACKGROUND: Recent evidence suggests that among patients receiving vancomycin, receipt of concomitant piperacillin-tazobactam increases the risk of nephrotoxicity. Well-controlled, adequately powered studies comparing rates of acute kidney injury (AKI) among patients receiving vancomycin + piperacillin-tazobactam (VPT) compared to similar patients receiving vancomycin + cefepime (VC) are lacking. In this study we compared the incidence of AKI among patients receiving combination therapy with VPT to a matched group receiving VC. METHODS: A retrospective, matched, cohort study was performed. Patients were eligible if they received combination therapy for ≥48 hours. Patients were excluded if their baseline serum creatinine was >1.2mg/dL or they were receiving renal replacement therapy. Patients receiving VC were matched to patients receiving VPT based on severity of illness, intensive care unit status, duration of combination therapy, vancomycin dose, and number of concomitant nephrotoxins. The primary outcome was the incidence of AKI. Multivariate modeling was performed using Cox proportional hazards. RESULTS: A total of 558 patients were included. AKI rates were significantly higher in the VPT group than the VC group (81/279 [29%] vs 31/279 [11%]). In multivariate analysis, therapy with VPT was an independent predictor for AKI (hazard ratio = 4.27; 95% confidence interval, 2.73-6.68). Among patients who developed AKI, the median onset was more rapid in the VPT group compared to the VC group (3 vs 5 days P =< .0001). CONCLUSION: The VPT combination was associated with both an increased AKI risk and a more rapid onset of AKI compared to the VC combination.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciw709

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 184

Metadata

Authors
Navalkele, B., Pogue, J. M., Karino, S., Nishan, B., Salim, M., Solanki, S., Pervaiz, A., Tashtoush, N., Shaikh, H., Koppula, S., Koons, J., Hussain, T., Perry, W., Evans, R., Martin, E. T., Mynatt, R. P., Murray, K. P., Rybak, M. J., & Kaye, K. S.
Venue
Clinical Infectious Diseases
Published
2016-10-20
Volume
64
Issue
2
Pages
116-123
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2537843951
Cited by
184
References
0
FWCI
18.64
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin–Tazobactam Compared to Those on Vancomycin and Cefepime. https://app.cochat.ai/papers/10.1093/cid/ciw709
The paper
Navalkele, B., Pogue, J. M., Karino, S., Nishan, B., Salim, M., Solanki, S., Pervaiz, A., Tashtoush, N., Shaikh, H., Koppula, S., Koons, J., Hussain, T., Perry, W., Evans, R., Martin, E. T., Mynatt, R. P., Murray, K. P., Rybak, M. J., & Kaye, K. S. (2017). Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin–Tazobactam Compared to Those on Vancomycin and Cefepime. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciw709

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.